- Home
- SIG vs MIRM Comparison
SIG vs MIRM Comparison
Compare SIG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIG
- MIRM
- Stock Information
- Founded
- SIG 1950
- MIRM 2018
- Country
- SIG Bermuda
- MIRM United States
- Employees
- SIG N/A
- MIRM N/A
- Industry
- SIG Consumer Specialties
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- SIG Consumer Discretionary
- MIRM Health Care
- Exchange
- SIG Nasdaq
- MIRM Nasdaq
- Market Cap
- SIG 3.1B
- MIRM 3.3B
- IPO Year
- SIG N/A
- MIRM 2019
- Fundamental
- Price
- SIG $90.50
- MIRM $74.18
- Analyst Decision
- SIG Buy
- MIRM Strong Buy
- Analyst Count
- SIG 6
- MIRM 9
- Target Price
- SIG $100.67
- MIRM $73.89
- AVG Volume (30 Days)
- SIG 1.1M
- MIRM 994.4K
- Earning Date
- SIG 09-02-2025
- MIRM 08-06-2025
- Dividend Yield
- SIG 1.42%
- MIRM N/A
- EPS Growth
- SIG N/A
- MIRM N/A
- EPS
- SIG 3.04
- MIRM N/A
- Revenue
- SIG $6,778,700,000.00
- MIRM $429,161,000.00
- Revenue This Year
- SIG $1.41
- MIRM $52.71
- Revenue Next Year
- SIG $1.07
- MIRM $19.71
- P/E Ratio
- SIG $29.65
- MIRM N/A
- Revenue Growth
- SIG N/A
- MIRM 62.33
- 52 Week Low
- SIG $45.55
- MIRM $36.86
- 52 Week High
- SIG $106.28
- MIRM $76.02
- Technical
- Relative Strength Index (RSI)
- SIG 60.38
- MIRM 75.04
- Support Level
- SIG $85.31
- MIRM $73.12
- Resistance Level
- SIG $91.85
- MIRM $76.02
- Average True Range (ATR)
- SIG 3.72
- MIRM 2.39
- MACD
- SIG 0.62
- MIRM 0.09
- Stochastic Oscillator
- SIG 78.78
- MIRM 84.26
About SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.